| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2134892 | Experimental Hematology | 2008 | 10 Pages |
Abstract
We confirm that CB represents a good source for clinical ex vivo expansion of EPCs. However, because of high frequency of karyotype alterations, these cells cannot be considered free of risk in clinical application.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Mirko Corselli, Alessia Parodi, Massimo Mogni, Nadia Sessarego, Annalisa Kunkl, Franca Dagna-Bricarelli, Adalberto Ibatici, Sarah Pozzi, Andrea Bacigalupo, Francesco Frassoni, Giovanna Piaggio,